Under Therapeutic Pressure: ELCC Session Highlights How Tumor Switching is Reshaping the Treatment Landscape

… to develop complex resistance. Under therapeutic pressure, tumor evolution—or “switching”—can manifest in various ways, … transformation data and complex interpretation. “ctDNA is helpful if we witness systemic progression, …

Phase II Trial Evaluates Amivantamab Plus Lazertinib in EGFR-Mutant Lung Cancers With New or Progressing Brain Metastases or Leptomeningeal Disease

… the formal response criteria. However, when we examined CSF circulating tumor cells (CTCs), 67% of patients demonstrated a reduction in tumor burden. This discordance suggests that conventional …